Atea Pharmaceuticals (AVIR) Other Non-Current Assets (2019 - 2026)

Atea Pharmaceuticals' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets fell 30.63% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $3.0 million, a 30.63% decrease from a year earlier, with the FY2025 full-year figure at $3.1 million, up 1491.88% from the prior year.
• Other Non-Current Assets fell to $3.0 million in Q1 2026 per AVIR's latest filing, from $3.1 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $5.5 million in Q3 2025 and bottomed at $197000.0 in Q4 2024.
• The 5-year median for Other Non-Current Assets is $1.4 million (2023), against an average of $1.7 million.
• Across the five-year window, Other Non-Current Assets plunged 85.89% in 2024 and surged 1491.88% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $198000.0 in 2022, then soared by 605.05% to $1.4 million in 2023, then plunged by 85.89% to $197000.0 in 2024, then jumped by 1491.88% to $3.1 million in 2025, then fell by 2.81% to $3.0 million in 2026.
• Per Business Quant, the three latest AVIR Other Non-Current Assets figures stand at $3.0 million (Q1 2026), $3.1 million (Q4 2025), and $5.5 million (Q3 2025).